Bronchitol
The two studies were of similar design and encompass 643 patients from
11 countries. Over the 26 weeks of the two studies, patients treated
with Bronchitol had an average 7.3% improvement in lung function (FEV1)
compared to baseline (p<0.001) and a highly significant improvement
compared to patients in the control group (p<0.001). In the sub
group of patients who were also on rhDNase, patients taking Bronchitol
showed a 5.3% improvement from baseline (p<0.001), that was again
superior to the control group (p=0.020). In the sub group of patients
who were not on rhDNase, patients taking Bronchitol showed a 9.44%
improvement from baseline (p<0.001), that was also superior to the
control group (p=0.009). The overall rate per annum reduction in
exacerbations for patients on Bronchitol versus those on control was 25%
(NS) and the number of patients experiencing an exacerbation was 29%
lower for those taking Bronchitol (NS). This result was achieved in a
well treated patient population who overall had a very low rate of
exacerbations in the study.
Bronchitol
Bronchitol
Bronchitol
Bronchitol
Bronchitol
Bronchitol
Bronchitol
Bronchitol
No comments:
Post a Comment